Slok, Annerika H M
in ’t Veen, Johannes C C M
Chavannes, Niels H
van der Molen, Thys
Rutten-van Mölken, Maureen P M H
Kerstjens, Huib A M
Salomé, Philippe L
Holverda, Sebastiaan
Dekhuijzen, PN Richard
Schuiten, Denise
Asijee, Guus M
van Schayck, Onno C P
Article History
Received: 20 December 2013
Revised: 17 April 2014
Accepted: 9 May 2014
First Online: 10 July 2014
Competing interests
: OCPvS received several unrestricted institutional grants from Pfizer, Boehringer Ingelheim, AstraZeneca and GlaxoSmithKline. OCPvS is an Assistant editor of the <i>PCRJ</i>, but was not involved in the editorial review of, nor the decision to publish, this article. TvdM developed the CCQ, received grants, reimbursement for travel and fees for speaking, and is on the advisory boards of AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Teva and MSD. The Erasmus University, Institute for Medical Technology Assessment, where MPMHR-vM is employed, has received funding for designing and conducting cost-effectiveness studies of COPD drugs from multiple pharmaceutical companies (Boehringer Ingelheim, Nycomed, Pfizer). MPMHR-vM has received speaker fees and compensation for serving on the advisory boards of GSK, Boehringer Ingelheim, Pfizer, Nycomed and Novartis. MPMHR-vM does not own stock of any pharmaceutical company. PNRD has received reimbursements for attending symposia, fees for speaking and organising educational events, funds for research or fees for consulting from AstraZeneca, Boehringer-Ingelheim, Chiesi, Merck Sharp & Dohme, Mundipharma, Novartis, Takeda, Almirall and Teva. The remaining authors declare no conflict of interest.